Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Update on Therapeutic Advances in T-Cell Lymphoma: Live Webinar

Access Activity

Overview / Abstract:

T-cell lymphoma is a rare but deadly hematologic malignancy that is difficult to diagnose and has limited treatment options. Join us for this 2021 update to gain expert perspectives on:

- Differential diagnosis
- Clinical studies supporting the efficacy and safety of novel agents
- Emerging combination and sequential treatment strategies

In addition, our expert faculty provide evidence-based advice regarding:
- Tailoring treatment plans to individual patients
- Managing treatment-related adverse events
- Applying best practices for supportive care and patient safety
- And much more!

Due to the high demand for this live webinar, we are pleased to offer 2 dates and times:

Thursday, March 11, 2021 @ 12:00 PM EST
Monday, March 15, 2021 @ 3:00 PM EST

Statement of Need:

Each year, 74,240 new cases of non-Hodgkin lymphoma are diagnosed and 19,940 people die of the disease (ACS, 2020). Among these cases, 12% to 15% are classified as peripheral T-cell lymphomas (PTCL), which comprise more than 10 different T-cell lymphomas (Zain, 2020). The diagnosis of PTCL is challenging, and 26% are categorized as PTCL, not otherwise specified (PTCL-NOS). Prognosis is poor, with a 5-year overall survival of less than 30% (Zain, 2020). Other less common subtypes of TCL include anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma (ATL), angioimmunoblastic TCL, and cutaneous TCL (CTCL) (NCCN, 2020b). The most common CTCL subtype is mycosis fungoides (MF), which is generally indolent; however, because it frequently mimics symptoms associated with other skin conditions, it can be difficult to diagnose in its early stages. Over time, MF can spread across the skin; in advanced stages, it can demonstrate extracutaneous involvement, invading the lymph nodes, blood, or occasionally other organs (NCCN, 2020a). Some patients develop S├ęzary syndrome, a rare, aggressive form of MF that affects both the skin and peripheral blood. Furthermore, CTCL is often resistant to chemotherapy, and the treatment of patients with advanced disease remains challenging (Alpdogan et al, 2020).


Hematologist/oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with T-cell lymphoma (TCL).


Upon completion of this activity, participants should be able to:

1.) Apply guideline recommendations for the differential diagnosis of TCL
2.) Evaluate emerging efficacy and safety data on novel therapies for newly diagnosed and relapsed/refractory TCL
3.) Apply strategies for managing adverse events associated with novel TCL therapies


Mar 15, 2021


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Live / Seminar, Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Steven M. Horwitz, MD (Chairperson)
Member and Attending Physician
Memorial Sloan Kettering Cancer Center

Activity Specialities / Related Topics

Pharmacology, Oncology / Cancer / Radiation Therapy, Medication Safety, Hematology, Diagnosis / Assessment / Patient History, Adverse Drug Reactions / ADR

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from Kyowa Kirin and SeaGen.

Keywords / Search Terms

i3 Health T-cell lymphoma, TCL, oncology, hematology, CME, NCPD, CNE, MOC, ILNA, free CME, free NCPD, CNE, free CE, CE, i3 Health Free CE CME Seminar CE CME, lymphoma diagnosis, lymphoma cancer treatment, cutaneous lymphoma, lymphoma research,

LIVE Activity Location Details

03-11-2021 - 03-15-2021

i3 Health
United States of America

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map